FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914829541> ?p ?o ?g. }

• W2914829541 endingPage "4076" @default.
• W2914829541 startingPage "4076" @default.
• W2914829541 abstract "Abstract Introduction The measurement, analysis, and communication of treatment-related symptoms and their impact on the functioning of individuals in clinical trials is an area of interest to the medical community, the Food and Drug Administration and other regulatory agencies. Inclusion of GAs and PROs in early phase trials can characterize the heterogeneity of aging and guide development of therapies to benefit older adults. Despite evidence that GAs and PROs are feasible and predictive of outcome, few early phase trials have integrated them to inform on treatment tolerance. The aim of this analysis is to describe changes in GAs and PROs among older adults with R/R AML in a Phase 1b trial of BCL2 inhibitor venetoclax (Ven) with either MEK inhibitor cobimetinib (cobi) or MDM2 antagonist idasanutlin (idasa) (NCT02670044). Methods Patients (pts) aged ≥60 yrs who were ineligible for cytotoxic therapy/allogeneic stem cell transplant were enrolled in this open-label, multicenter study, designed to evaluate the safety, tolerability, and efficacy of Ven+cobi/idasa in R/R or secondary AML. GA measures were Short Physical Performance Battery (SPPB; gait speed, balance tests, chair stands), Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI) and Short Blessed Orientation Test (SBOT). Treatment-related symptoms were assessed via the PRO version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), administered electronically throughout treatment. GAs were administered at screening, Cycle (C) 2 Day (D) 1, C3D1, and C7D1; PRO-CTCAE was administered at C1D1, weekly during C1, for the first 3 weeks of C2 and C3, and monthly starting at C4D1. Mean GA scores were calculated over time for each treatment arm and pt-level heatmaps were created. The 'frequency', 'severity', 'interference', and 'presence' of PRO-CTCAE symptoms were reported at each assessment, with a longitudinal analysis to understand how symptoms changed over the course of treatment. Results As of April 6 2018, 64 pts had been treated with either Ven+cobi or Ven+idasa. Baseline characteristics were comparable between arms; respectively: median age, 72, 74 yrs; ECOG performance status 0-1, 83%, 82%; refractory disease, 63%, 56%. GA and PRO data were available in 52 and 38 pts, respectively. Screening of GAs identified a physically frail (mean SPPB score <9), cognitively intact (mean SBOT scores <4) pt population with comorbidities (Table 1). At baseline, PRO-CTCAE showed that >70% of pts 'never' or 'rarely' experienced nausea, vomiting or diarrhea; >75% and >50% reported 'none' or 'mild' decreased appetite and fatigue, respectively. In both arms, pt numbers reduced over C1-3, with 8 pts in the Ven+cobi and 6 pts in the Ven+idasa arms providing data at C3D1; this was largely due to attrition on study. Pts reported that their worst post-baseline symptom was 'frequent' or 'almost constant' symptoms of nausea (55%), diarrhea (71%), and vomiting (5%) at some point, and 'severe' or 'very severe' decreased appetite (55%) or fatigue (55%). Variations in the worst post-baseline symptoms were observed between treatment arms, although this was not statistically tested. Symptoms tended to increase and decrease with the start and end of each treatment cycle and appeared worse during C1 for Ven+cobi (Figure 1). Despite differences in symptoms during the cycle, there did not appear to be changes in mean SPPB scores from baseline to C2, no cognitive impairment during treatment, and little to no increase in comorbidity burden. These results may be influenced by a reduction in pt numbers in each treatment arm over subsequent assessments. Conclusion PROs from this Phase 1b study indicate an increased frequency of treatment-related symptoms, in particular, nausea, diarrhea, vomiting, decreased appetite and fatigue, in older AML pts treated with Ven+cobi or Ven+idasa compared with pre-treatment. PROs and GAs can provide additional complementary insight into the older pt's treatment experience on early phase clinical trials that can inform design of later-phase studies. However, strategies to address missing data will be important for maximizing value gained. Disclosures Klepin: Genentech Inc: Consultancy. Campinha-Bacote:Genentech Inc: Employment. Hong:Genentech Inc/Roche: Employment, Other: Ownership interests PLC. Phuong:Genentech Inc: Employment, Equity Ownership, Other: Ownership interests PLC. Wang:Genentech Inc: Employment; F. Hoffmann-La Roche Ltd: Equity Ownership. Mobasher:F. Hoffmann-La Roche Ltd: Other: Ownership interests non-PLC; Genentech Inc: Employment. Trask:Genentech Inc: Employment; F. Hoffmann-La Roche: Employment." @default.
• W2914829541 created "2019-02-21" @default.
• W2914829541 creator A5029311650 @default.
• W2914829541 creator A5031784520 @default.
• W2914829541 creator A5040157636 @default.
• W2914829541 creator A5045381939 @default.
• W2914829541 creator A5071741465 @default.
• W2914829541 creator A5072546509 @default.
• W2914829541 creator A5076036593 @default.
• W2914829541 date "2018-11-29" @default.
• W2914829541 modified "2023-10-14" @default.
• W2914829541 title "Geriatric Assessment (GA) Measures and Patient-Reported Outcomes (PROs) Among Older Adults Treated in a Phase 1b Study for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)" @default.
• W2914829541 doi "https://doi.org/10.1182/blood-2018-99-116038" @default.
• W2914829541 hasPublicationYear "2018" @default.
• W2914829541 type Work @default.
• W2914829541 sameAs 2914829541 @default.
• W2914829541 citedByCount "0" @default.
• W2914829541 crossrefType "journal-article" @default.
• W2914829541 hasAuthorship W2914829541A5029311650 @default.
• W2914829541 hasAuthorship W2914829541A5031784520 @default.
• W2914829541 hasAuthorship W2914829541A5040157636 @default.
• W2914829541 hasAuthorship W2914829541A5045381939 @default.
• W2914829541 hasAuthorship W2914829541A5071741465 @default.
• W2914829541 hasAuthorship W2914829541A5072546509 @default.
• W2914829541 hasAuthorship W2914829541A5076036593 @default.
• W2914829541 hasConcept C126322002 @default.
• W2914829541 hasConcept C143998085 @default.
• W2914829541 hasConcept C1862650 @default.
• W2914829541 hasConcept C197934379 @default.
• W2914829541 hasConcept C2778375690 @default.
• W2914829541 hasConcept C535046627 @default.
• W2914829541 hasConcept C71924100 @default.
• W2914829541 hasConceptScore W2914829541C126322002 @default.
• W2914829541 hasConceptScore W2914829541C143998085 @default.
• W2914829541 hasConceptScore W2914829541C1862650 @default.
• W2914829541 hasConceptScore W2914829541C197934379 @default.
• W2914829541 hasConceptScore W2914829541C2778375690 @default.
• W2914829541 hasConceptScore W2914829541C535046627 @default.
• W2914829541 hasConceptScore W2914829541C71924100 @default.
• W2914829541 hasIssue "Supplement 1" @default.
• W2914829541 hasLocation W29148295411 @default.
• W2914829541 hasOpenAccess W2914829541 @default.
• W2914829541 hasPrimaryLocation W29148295411 @default.
• W2914829541 hasRelatedWork W2000054321 @default.
• W2914829541 hasRelatedWork W2001146581 @default.
• W2914829541 hasRelatedWork W2052309381 @default.
• W2914829541 hasRelatedWork W2075126241 @default.
• W2914829541 hasRelatedWork W2080987332 @default.
• W2914829541 hasRelatedWork W2107697672 @default.
• W2914829541 hasRelatedWork W2518309888 @default.
• W2914829541 hasRelatedWork W2567400702 @default.
• W2914829541 hasRelatedWork W2789023463 @default.
• W2914829541 hasRelatedWork W3120506851 @default.
• W2914829541 hasVolume "132" @default.
• W2914829541 isParatext "false" @default.
• W2914829541 isRetracted "false" @default.
• W2914829541 magId "2914829541" @default.
• W2914829541 workType "article" @default.